HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 801–900 of 1,000
Che, J., Shen, W., Deng, Y., Dai, Y., Liao, Y., Yuan, X., & Zhang, P. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.05.030 · Cited by 15
RetractedOu, X., & Lv, W. (2020) · Future Oncology · doi:10.2217/fon-2019-0692 · Cited by 15
c-Maf: a bad influence in the education of macrophages
Conejo-Garcia, J. R., & Rodríguez, P. C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135444 · Cited by 16
Sharma, V., Aggarwal, A., Jacob, J., & Sahni, D. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13021 · Cited by 16
Xia, M., Shan, J., Li, Y. P., Zhou, Y. N., Guo, Y. J., Sun, G. X., Wu, W. Q., & Feng, L. (2014) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12094 · Cited by 15
Kidiyoor, A., Schettini, J. L., Besmer, D. M., Rego, S. L., Nath, S., Curry, J. M., Roy, L. D., Dréau, D., & Mukherjee, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00067 · Cited by 14
Lattanzi, C., Bianchetto-Aguilera, F. M., Donini, M., Pettinella, F., Caveggion, E., Castellucci, M., Gasperini, S., Mariotti, B., Signoretto, I., Cantini, M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2521396 · Cited by 17
Ponzo, M., Drufuca, L., Buracchi, C., Sindoni, M. M., Nucera, S., Bugarin, C., Bason, R., Rossetti, G., Bonnal, R. J. P., Meli, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011768 · Cited by 18
Cai, Y., Li, K., Lin, J., Liang, X., Xu, W., Zhan, Z., Xue, S., Zeng, Y., Chai, P., Mao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910490 · Cited by 16
MDSCs: The Key Players in the Formation of Pre-Metastatic Niche
Cui, W., Wang, Z., Lv, J., Qin, Y., & Shi, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2803058 · Cited by 16
Smith, V., Lee, D. C. H., Reardon, M., Shabbir, R., Sahoo, S., Hoskin, P., Choudhury, A., Illidge, T., & West, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108956 · Cited by 19
Targeting immune checkpoints on myeloid cells: current status and future directions
Ma, C., Li, Y., Li, M., Lv, C., & Tian, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03856-6 · Cited by 17
Immunocombination Therapy for High-Risk Neuroblastoma
Kroesen, M., Lindau, D., Hoogerbrugge, P. M., & Adema, G. J. (2012) · Immunotherapy · doi:10.2217/imt.11.169 · Cited by 14
Iyengar, S., Zhan, C., Lu, J., Korngold, R., & Schwartz, D. H. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.04.029 · Cited by 17
Spagnuolo, R. D., Brich, S., Bozzi, F., Conca, E., Castelli, C., Tazzari, M., Maestro, R., Brenca, M., Gualeni, A. V., Gloghini, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7523 · Cited by 15
Croci, D. O., Méndez‐Huergo, S. P., Cerliani, J. P., & Rabinovich, G. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_29 · Cited by 16
The disruption of hematopoiesis in tumor progression
Wang, X., & Li, Y. (2019) · Blood Science · doi:10.1097/bs9.0000000000000001 · Cited by 16
A review of tasquinimod in the treatment of advanced prostate cancer
Heer, R., Williamson, S. C., & Hartley, A. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31500 · Cited by 21
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?
Patel, P., Schutzer, S. E., & Pyrsopoulos, N. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i3.242 · Cited by 17
Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells
Janssen, N., Speigl, L., Pawelec, G., Niessner, H., & Shipp, C. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.012 · Cited by 15
Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion
Arianfar, E., Shahgordi, S., & Memarian, A. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1845670 · Cited by 16
Cutting edge: Metabolic immune reprogramming, reactive oxygen species, and cancer
Aria, H., Ghaedrahmati, F., & Ganjalıkhani-Hakemi, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30303 · Cited by 14
Essentially all models are wrong, but some are useful
Simard, J. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001769 · Cited by 13
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 18
The role of peripheral innate immune cells in Alzheimer’s disease progression
Cao, Y., Tang, K., Ma, P., Zhang, R., Yang, Y., Li, T., Zhang, Y., & Peng, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616939 · Cited by 19
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy
Savardekar, H., Stiff, A. R., Liu, A., Wesolowski, R., Schwarz, E. J., Garbarine, I. C., Duggan, M. C., Zelinskas, S., Li, J., Lapurga, G., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181975 · Cited by 13
Zhou, Z., Zhong, H., Wang, H., Wang, S., Kridis, W. B., Wang, R., Shen, K., Wang, Z., & Huang, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-03797-1 · Cited by 18
The Metabolic Control of Myeloid Cells in the Tumor Microenvironment
Ramel, E., Lillo, S., Daher, B., Fioleau, M., Daubon, T., & Saleh, M. (2021) · Cells · doi:10.3390/cells10112960 · Cited by 17
The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease
Twum, D. Y. F., Burkard-Mandel, L. E., & Abrams, S. I. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr1116-479r · Cited by 14
Xue, R., Yang, Y., Wu, J., Chen, J., Chen, Q., Ren, R., Zhang, Q., Hu, Y., & Yin, D. (2019) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2019.101642 · Cited by 13
Steinberger, K. J., Forget, M. A., Bobko, A. A., Mihalik, N. E., Gencheva, M., Roda, J. M., Cole, S. L., Mo, X. M., Hoblitzell, E. H., Evans, R., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000185 · Cited by 16
Isaacs, J. T., Dalrymple, S. L., Rosen, D. M., Hammers, H. J., OLSSON, A. G., & Leanderson, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2378 · Cited by 14
Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation
Chioda, M., Marigo, I., Mandruzzato, S., Mocellin, S., & Bronte, V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00034-8 · Cited by 16
Yu, Y., Wang, Y., Wang, Y., Wang, X., Liu, Y., Wang, J., Du, C., Wang, L., Li, M., Luo, F., et al. (2016) · Scientific Reports · doi:10.1038/srep34239 · Cited by 14
Myeloid‐Derived Suppressor Cells
Toor, S. M., & Elkord, E. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0024245 · Cited by 14
Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy
Sureshbabu, S. K., Godbole, J. H., Vaibhaw, A., & Chiplunkar, S. V. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00013 · Cited by 13
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
Bizymi, N., Matthaiou, A. Μ., Matheakakis, A., Voulgari, I., Aresti, N., Zavitsanou, K., Karasachinidis, A., Mavroudi, I., Pontikoglou, C. G., & Papadaki, H. Α. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185326 · Cited by 16
Myeloid-derived suppressor cells in head and neck squamous cell carcinoma
He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 15
Gao, F., Dong, J., Xue, C., An, L., Zhang, T., Wang, W.-J., Ou, C., & Dong, X. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101831 · Cited by 12
Effect of tumor microenvironment on ferroptosis: inhibition or promotion
Xia, Z., & Quan, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155511 · Cited by 12
Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy
Zhou, H., Yu, C., & Wei, H. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123818 · Cited by 12
Mitochondria, Autophagy and Inflammation: Interconnected in Aging
Silva, R. C. M. C. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01231-x · Cited by 13
Microbial-induced trained immunity for cancer immunotherapy
Vuscan, P., Kischkel, B., Joosten, L. A. B., & Netea, M. G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100074 · Cited by 18
Shi, S., Tao, L., Song, H., Chen, L., & Huang, G. (2014) · Apmis · doi:10.1111/apm.12235 · Cited by 13
Can the Suppressive Activity of Myeloid-Derived Suppressor Cells Be “Chop”ped?
Condamine, T., & Gabrilovich, D. I. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.016 · Cited by 12
Self-citationSergio Bracarda, A., Porta, C., Sabbatini, R., & Rivoltini, L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.009 · Cited by 12
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy
Laureano, R. S., Vanmeerbeek, I., Sprooten, J., Govaerts, J., Naulaerts, S., & Garg, A. D. (2023) · Immunological Reviews · doi:10.1111/imr.13287 · Cited by 13
The impact of hypoxia on oncolytic virotherapy
Guo, Z. S. (2011) · Virus Adaptation and Treatment · doi:10.2147/vaat.s17832 · Cited by 19
Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer
Talarico, G., Orecchioni, S., Falvo, P., & Bertolini, F. (2025) · Cancers · doi:10.3390/cancers17132251 · Cited by 14
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 16
Babl, N., Voll, F., Martowicz, A., Bruß, C., Maddaloni, M., Schmidl, C., Rehli, M., Loipfinger, S., Strieder, N., Gebhard, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218209 · Cited by 11
Bertrand, B. P., Heim, C. E., Koepsell, S. A., & Kielian, T. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad158 · Cited by 12
Liu, Y., Lin, H., Zhong, W., Zeng, Y., Zhou, G., Chen, Z., Huang, S., Zhang, L., & Liu, X. (2024) · Clinical Oral Investigations · doi:10.1007/s00784-024-05645-y · Cited by 13
Kim, J., Choi, J. Y., Min, H., & Hwang, K. W. (2024) · Immune Network · doi:10.4110/in.2024.24.e26 · Cited by 12
Wang, W., Zheng, Y., Wu, Z., Wu, M., Chen, Y., Zhang, Y., Fu, S., & Wu, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05469-0 · Cited by 13
Xiao, M., Zhou, J., Zhang, W., Ding, Y., Guo, J., Liang, X., Zhu, J., Jiao, X., Zhai, Z., & Wang, H. (2024) · CytoJournal · doi:10.25259/cytojournal_165_2024 · Cited by 11
Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies
Runtsch, M. C., Angiari, S., & Kargl, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108893 · Cited by 13
Dietz, S., Schwarz, J., Velić, A., González-Menéndez, I., Quintanilla‐Martínez, L., Casadei, N., Marmé, A., Poets, C. F., Gille, C., & Köstlin‐Gille, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.787468 · Cited by 12
JEV Infection Induces M-MDSC Differentiation Into CD3+ Macrophages in the Brain
Zhang, N., Gao, X., Zhang, W., Xiong, J., Cao, X., Fu, Z. F., & Cui, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838990 · Cited by 16
Myeloid-derived suppressor cells: A new emerging player in endometriosis
Zhang, T., He, Y., Man, G. C. W., Ding, Y., Wang, C. C., & Chung, J. P. W. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.004 · Cited by 13
Tumour suppressor PTEN activity is differentially inducible by myo‐inositol phosphates
Grzymajło, K., Hafny‐Rahbi, B. E., & Kiéda, C. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17699 · Cited by 10
Rühle, J., Ginzel, M., Dietz, S., Schwarz, J., Lajqi, T., Beer‐Hammer, S., Poets, C. F., Gille, C., & Köstlin‐Gille, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097763 · Cited by 11
Conway, J. W., Braden, J., Lo, S., Scolyer, R. A., Carlino, M. S., Menzies, A. M., Long, G. V., & da Silva, I. P. (2023) · Cancers · doi:10.3390/cancers15205012 · Cited by 11
Chmielewski, M. M., & Abken, H. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.7 · Cited by 11
Epigenetic regulation of the hypoxic response
Nam, H. J., & Baek, S. H. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.11.007 · Cited by 11
Immunometabolism Modulation in Therapy
Monferrer, E., Sanegre, S., Vieco-Martí, I., López-Carrasco, A., Fariñas, F., Villatoro, A. J., Abanades, S., Mañes, S., de la Cruz‐Merino, L., Noguera, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070798 · Cited by 13
The influence of neuro-tumor interactions on tumorigenesis and therapeutic response
Wang, X., Yan, Y., Li, L., Li, T., Thakur, A., Zhang, K., Li, J., Zhan, C., Tang, H., Xu, Z., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00752-w · Cited by 15
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
Norata, D., Peri, M., Giammalva, G. R., Lupica, A., Paolini, F., Incorvaia, L., Badalamenti, G., Gristina, V., Galvano, A., Russo, A. D., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13010144 · Cited by 11
Mahanti, K., Saha, J., Sarkar, D., Pramanik, A., Chattopadhyay, N. R., & Bhattacharyya, S. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae013 · Cited by 10
MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech
Cioccarelli, C., & Molon, B. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac025 · Cited by 11
Mudassar, F., Shen, H. M., Cook, K. M., & Hau, E. K. C. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13416 · Cited by 10
Myeloid-derived suppressor cells and pulmonary hypertension
Zhang, H., Li, Q., Li, Y., Tang, X., Gu, L., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189195 · Cited by 13
Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri, M., Najafi, A., Rahimi, A. R., Behranvand, N., Kazemi, M. H., Khorramdelazad, H., & Falak, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110470 · Cited by 12
Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment
Zhu, D., Su, C., Li, J. J., Li, A. W., Luv, Y., & Fan, Q. (2023) · World Journal of Oncology · doi:10.14740/wjon1645 · Cited by 10
Myeloid-Derived Suppressor Cells and Pulmonary Hypertension
Bryant, A. J., Mehrad, B., Brusko, T. M., West, J. D., & Moldawer, L. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082277 · Cited by 11
Fatty Acid Mediators in the Tumor Microenvironment
Khadge, S., Sharp, J. G., Thiele, G. M., McGuire, T. R., & Talmadge, J. E. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_8 · Cited by 14
Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
Zheng, Z., Bian, C., Wang, H., Su, J., Meng, L., Xin, Y., & Jiang, X. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138383 · Cited by 12
Guth, A., Hafeman, S., & DOW, S. W. (2012) · OncoImmunology · doi:10.4161/onci.21317 · Cited by 12
Maru, Y. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036897 · Cited by 10
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
Wang, C., Zou, R.-Q., & He, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344821 · Cited by 10
The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer
Mandal, S. K., Yadav, P., & Sheth, R. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116237 · Cited by 11
Immune-metabolic crosstalk in HNSCC: mechanisms and therapeutic opportunities
Qin, X., Wu, H., Pan, J., Kang, K., Shi, Y., & Bu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553284 · Cited by 12
Tumor hypoxia shapes natural killer cell anticancer activities
Retamal, M. A., Salazar‐Onfray, F., González, F. E., & Tittarelli, A. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02557-6 · Cited by 10
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunity
Chang, T., Friedman, J., Clavijo, P. E., Robbins, Y. L., Craveiro, M., Huynh, A. P., Dar, M. S., Yang, X., Cao, Y., Sievers, C. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adz2273 · Cited by 12
Lee, A., Park, H., Lim, S., Lim, J., Koh, J., Jeon, Y. K., Yang, Y. D., Lee, M., & Lim, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005699 · Cited by 9
Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress
Andrés, C., de la Lastra, J. M. P., Juan, C., Plou, F. J., & Pérez‐Lebeña, E. (2023) · Vaccines · doi:10.3390/vaccines11020218 · Cited by 10
Sumi, S., Umemura, N., Takayama, E., Ohkoshi, E., Adachi, M., Mizuno‐Kamiya, M., Inagaki, T., Kawaki, H., Sumitomo, S., & Kondoh, N. (2017) · Oncology Reports · doi:10.3892/or.2017.5575 · Cited by 9
Lisini, D., Lettieri, S., Nava, S., Accordino, G., Frigerio, S., Bortolotto, C., Lancia, A., Filippi, A. R., Agustoni, F., Pandolfi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169014 · Cited by 8
Puerarin decreases hypoxia inducible factor-1 alpha in the hippocampus of vascular dementia rats.
Wu, H., Wang, H., Zhang, B., Zhang, G., Zhang, R., & Zhang, L. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.06.003 · Cited by 9
Zhu, X., Li, Z., Chen, L., Li, L., Ouyang, M., Zhou, H., Xiao, K., Lin, L., Chu, P. K.-H., Zhou, C. Y., et al. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01044-x · Cited by 10
Lipids: Driving Forces in the Underlying Biology of Carcinogenesis
Chakraborty, S., Kumar, A. S., & Banerjee, S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00170 · Cited by 10
Ran, B., Xiao, L., Liu, Y., Zhang, C., Kong, L., Zhang, Y., Gu, X., Jiang, C., & Wu, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.025 · Cited by 16
Kim, M.-S., Lee, J., Lee, J. E., An, J. H., Heo, J. Y., & Yeo, M. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01604-z · Cited by 16
Tolerogenic pDCs: spotlight on Foxo3
Bronte, V. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57190 · Cited by 8
Keränen, M. A. I., Raissadati, A., Nykänen, A. I., Dashkevich, A., Tuuminen, R., Krebs, R., Johnson, R. S., Syrjälä, S. O., & Lemström, K. (2018) · Transplant International · doi:10.1111/tri.13310 · Cited by 8
Circulating Myeloid Regulatory Cells: Promising Biomarkers in B-Cell Lymphomas
Ferrant, J., Lhomme, F., Gallou, S. L., Irish, J. M., & Roussel, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.623993 · Cited by 9
Blanco, E., Ibáñez-Vea, M., Hernandez, C., Drici, L., de Morentin, X. M., Gato, M., Ausín, K., Bocanegra, A., Zuazo, M., Chocarro, L., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060542 · Cited by 8
Estrogens and the Schrödinger’s Cat in the Ovarian Tumor Microenvironment
Gjorgoska, M., & Rižner, T. L. (2021) · Cancers · doi:10.3390/cancers13195011 · Cited by 9
Zhong, X., He, X., Wang, Y., Hu, Z., Yu, D., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Immunology Research · doi:10.1155/2022/9935705 · Cited by 10
Immune Cell Metabolism and Immuno-Oncology
Patel, C. H., & Powell, J. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-042605 · Cited by 11
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.